In a study of clonazepam pharmacokinetics following a single 3 mg dose [40], the highest peak urine concentration of 7-aminoclonazepam (~ 183 ng/mL) recorded in all study participants would still be below the reported concentrations of 7-aminoclonazepam necessary to produce a positive screening result in all currently marketed benzodiazepine screening immunoassays (dashed bracket in Figure ​Figure2B;2B; Additional file Inhibitors,research,lifescience,medical 1, tab C). Even

with chronic administration of clonazepam, urine concentrations of 7-aminoclonazepam may still be below the positive cutoff for most benzodiazepine screening immunoassays in clinical situations. Currently marketed benzodiazepine screening assays also have difficulty in detecting the use of lorazepam. Studies of lorazepam pharmacokinetics following oral or parenteral administration show that very little unchanged drug is excreted in the urine, with the majority appearing as the www.selleckchem.com/products/INCB18424.html glucuronide metabolite [41,42]. Lorazepam glucuronide has low structural similarity to diazepam (Tanimoto similarity = 0.561) and is detected much more poorly by Inhibitors,research,lifescience,medical the marketed assays than unconjugated lorazepam (Additional file 1, tab C). Some marketed benzodiazepine immunoassays can include a separate step to cleave the glucuronide bonds (e.g., by enzymatic or chemical reaction), resulting in unconjugated drugs. Inhibitors,research,lifescience,medical For a drug such as lorazepam, where the glucuronide metabolite is the predominant form in

the urine, cleaving the glucuronide bonds would be predicted to enhance the detection rate. Some marketed assays (e.g., Syva EMIT-H® and Roche Online KIMS®) incorporate a

glucuronide cleavage step in the reaction, while still maintaining rapid analysis times [43,44]. Cocaine assays All cocaine screening Inhibitors,research,lifescience,medical immunoassays Inhibitors,research,lifescience,medical currently marketed in the United States use antibodies raised against benzoylecognine, one of the two major cocaine metabolites in humans [7], as the antigenic target (Additional file 1, tab T). Thus, the marketed assays can be termed more precisely ‘cocaine metabolite screening assays’ or ‘benzoylecgonine screening assays’. Currently these marketed assays detect cocaine (parent drug) weakly, with cross-reactivities equal to 300 ng/mL benzoylecgonine only occurring Brefeldin_A at cocaine concentrations ranging from 10,000 ng/mL (Abbott AxSYM) to 80,000 ng/mL (Syva EMIT) (Additional file 1, tab F; Figure ​Figure3A).3A). In clinical practice, this means that very recent use of cocaine, even in large amounts, may fail to trigger a positive screen if too little time has elapsed for the metabolism of the parent drug to benzoylecgonine to occur. The marketed assays also vary in detection of other cocaine metabolites such as ecgonine, ecgonine methyl ester (the second major cocaine metabolite in most individuals) [7], and benzylnorecgonine (Additional file 1, tab F; Figure ​Figure3A),3A), potentially leading to different results if a patient sample is tested on more than one immunoassay system.